AUTHORS
Caroline Spaner, MD, Suraj Bansal, BHSc2, Amulya Bhagirath3, Andy Zeng, MD, PHD4, Jessie Medeiros, PhD5, Aniket Bankar, MD, MSc, DM, MBBS6, Jose-Mario Capo-Chichi, MD, PhD7, Verna Cheung, BScN, RN MN CON(C)8, Jessica Danquah, CCPA9, Marta Davidson, PhD MD10, James A. Kennedy, MD PhD11, Dawn Maze Sr, MD12, Hassan Sibai, MD, Msc, BSc13, Vikas Gupta, MD FRCP, FRCPath14
AFFILIATIONS
1 Princess Margaret Cancer Centre, Toronto, Ontario, Canada
2 Princess Margaret Cancer Centre, Toronto, Ontario, Canada
3 Princess Margaret Cancer Centre, Toronto, Ontario, Canada
4 Princess Margaret Cancer Centre, Toronto, Ontario, Canada
5 Princess Margaret Cancer Centre, Toronto, Ontario, Canada
6 Princess Margaret Cancer Centre, Toronto, Ontario, Canada
7 Princess Margaret Cancer Centre, Toronto, Ontario, Canada
8 Princess Margaret Cancer Centre, Toronto, Ontario, Canada
9 Princess Margaret Cancer Centre, Toronto, Ontario, Canada
10 Princess Margaret Cancer Centre, Toronto, Ontario, Canada
11 Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
12 Princess Margaret Cancer Centre, Toronto, Ontario, Canada
13 Princess Margaret Cancer Centre, Toronto, Ontario, Canada
14 Princess Margaret Cancer Centre, Toronto, Ontario, Canada
ABSTRACT
Background
JAK inhibitor (JAKi) therapy is the mainstay of therapeutic options for myelofibrosis (MF). Approximately 50% of the MF patients fail JAKi therapy by 2 years. Biomarkers that can predict JAKi failure is an area of unmet clinical need. Absolute neutrophil count (ANC), absolute monocyte count (AMC), and absolute lymphocyte count (ALC) are universally available clinical parameters, and some studies have evaluated neutrophil-to-lymphocyte Ratio (NLR) and monocyte-to-lymphocyte Ratio (MLR) as prognostic/predictive biomarkers in myeloproliferative neoplasms. However, their role as predictive biomarkers of JAKi failure in MF is not defined. Our study addresses this gap by evaluating the impact of ANC, AMC, NLR and MLR in predicting JAKi failure.
Methodology:
We used the Princess Margaret MPN registry (NCT 02760238) to identify patients with primary MF including pre-fibrotic MF, and or post-essential thrombocythemia and post-polycythemia MF in chronic phase, treated with ruxolitinib or momelotinib as first line therapy. Patients with concomitant diagnosis of a second cancer or lymphoid malignancy were excluded. The first day of the start of JAKi was the index date. Baseline patient, disease and treatment related values were obtained at index date. The primary end point of interest was cumulative risk of JAKi failure. Secondary end points were overall survival and cumulative risk of blast phase (BP) transformation. JAKi failure was defined as per the Canadian MPN Group consensus criteria (Gupta V, et al, JCO OP 2020). Survival analyses were performed using the Kaplan-Meier method. JAKi and BP transformation were additionally modeled with cumulative incidence functions. Multivariable models were performed to adjust for DIPSS category, number of high molecular risk (HMR) mutations, and transfusion requiring baseline anemia. HMR was defined as pathogenic or likely pathogenic mutations in ASXL1, SRSF2, IDH1/2, EZH2, or U2AF1Q157.
Results
A total of 371 MF patients who met study eligibility are included in this analysis. Median age of participants was 67 years (range 26-89), and 174 (47%) were male. Median baseline values were 8.2 (range: 0.2-97.4) for ANC, 0.5 (range: 0.0-19.4) for AMC, 5.9 (range: 0.4-95.5) for NLR, and 0.4 (range: 0.0-5.8) for MLR. 104 patients (28%) had AMC of 1 x 109/L or higher.
43 patients (12%) had transfusion requiring anemia at index date. By DIPSS, 67 (18%) were high risk, 101 (27%) were Int-1, 194 (52%) were Int-2, and 9 (2%) were low risk. Driver mutations included: JAK2, 60%; CALR 27%; MPL 9%; and 5% were triple negative. 278 (75%) had NGS available, and of those, 150 (54%) had no HMR, 85 (31%) had 1 HMR, 43 (15%) had 2 or more HMR. Median follow-up was 1046 days (range 4-5111). Of the 371 patients, 333 (90%) were treated with ruxolitinib, and 38 (10%) were treated with momelotinib. 159 patients (43%) experienced JAKi failure, 37 (10%) transformed to AML, and 174 (47%) died.
In the multivariate analysis, among the blood count-based biomarkers of interest, only AMC was independently associated with higher risk of JAKi failure (HR 1.21, 95% CI 1.02-1.43, p=0.03). Median time to JAKi failure was 227 days (range: 137-722) in patients with an AMC of 1 x 109/L or higher, versus 440 days (range: 204-1119) in patients with an AMC less than 1 x 109/L. High risk DIPSS (HR 1.90, 95% CI 1.16-3.11) and presence of HMR (HR 1.72 (95% CI 1.16-2.540, p = 0.01) were other independent factors associated with higher risk of JAKi failure.
No association of ANC, AMC, NLR or MLR was observed with BP transformation or overall survival. Patients with DIPSS Int-2 (HR 1.71 (95% CI 1.08-2.70), p = 0.02), DIPSS high risk (HR 3.23 (95% CI 1.89-5.52), p <0.01) and presence of 1 HMR (HR 1.91 (95% CI 1.29-2.84), p <0.01) or 2 or more HMR (HR 2.55 (95% CI 1.61-4.05), p <0.01) were associated with adverse survival.
Conclusions
Monocytosis at the time JAKi therapy initiation is an independent risk factor for higher risk of JAKi failure. These results suggest that the underlying disease biology of MF may carry prognostic value outside of existing clinical risk scores. No association of ANC, NLR or MLR ratio was observed with JAKi failure.
DISCLOSURES
Caroline Spaner, MD: No relevant conflicts of interest to declare.